Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina, Inc. (NASDAQ: ILMN) has launched Illumina Connected Analytics (ICA), a cloud-based bioinformatics solution designed to facilitate management and analysis of multi-omic data. The platform aims to help researchers like those at the Montreal Neurological Institute and the Munich Leukemia Laboratory handle larger data volumes efficiently. With features emphasizing security, scalability, and cost-effectiveness, ICA enhances users' ability to process genomic data generated from over 17,000 sequencing systems. ICA will be available starting January 28, 2021.
Illumina (NASDAQ: ILMN) has unveiled new oncology partnerships, reaffirming its commitment to precision oncology tools during the 39th Annual J.P. Morgan Healthcare Conference. The company introduced TruSight Oncology 500 (TSO 500), a comprehensive pan-cancer assay identifying 523 biomarkers using DNA and RNA from tumors. Illumina is expanding its partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to develop companion diagnostics and enhance treatment selection. A new IVD test based on TSO 500 is under regulatory review, with a launch expected in the U.S. and Europe this year.
Illumina (Nasdaq: ILMN) has partnered with Helix to enhance U.S. surveillance of SARS-CoV-2 variants, with support from the CDC. Their collaboration aims to identify and monitor emerging strains, having already detected B.1.1.7 in multiple states. This initiative will expand genomic surveillance efforts, allowing for timely responses to changes in the virus's pathogenicity and treatment efficacy. Both companies emphasize the importance of genomic data in adapting public health strategies to combat COVID-19 variants.
Illumina (NASDAQ:ILMN) announced that its executives will speak at the J.P. Morgan Virtual Healthcare Conference on January 11, 2021. The presentation is scheduled for 11:00 AM Pacific Time, followed by a Q&A session starting at approximately 11:20 AM. Investors can access the live webcast under the Investor Info section on www.illumina.com. Replays will be available for at least 30 days after the event. Illumina is a leader in DNA sequencing, focusing on innovations that enhance human health across various markets, including oncology and reproductive health.
Illumina and Harvard Pilgrim Health Care have entered a risk-sharing agreement to provide whole-genome sequencing (WGS) to select members, starting January 1, 2021. This initiative aims to expedite the diagnosis of genetic disorders in pediatric patients, potentially alleviating lengthy and expensive diagnostic processes that can exceed $20,000. The partnership is grounded in over 20 peer-reviewed studies showing WGS's clinical effectiveness in over 3,000 patients. Both organizations will evaluate the impact of WGS on healthcare expenses while working to enhance patient outcomes.
Illumina (NASDAQ:ILMN) announces its executives will present at the Piper Sandler Annual Healthcare Conference on December 3, 2020, at 1:30 PM Eastern Time. Interested investors can participate via a live webcast available in the Investor Info section of Illumina's website. The replay will be accessible for 30 days post-event. Illumina leads in DNA sequencing and array-based technologies, focusing on enhancing human health through innovative genomic solutions. For more details, visit www.illumina.com.
Illumina (NASDAQ: ILMN) has launched the P3 high-output flow cell for its NextSeq 2000 Sequencing System, significantly enhancing its sequencing capabilities. This new flow cell offers 1.1 billion reads per run, nearly tripling the output of previous models. It is expected to empower researchers by expanding project potential while optimizing costs. The NextSeq 1000, with a more accessible price for 400 million reads, is also available, featuring rapid analysis and cloud-based technology. These developments aim to simplify workflows and foster innovation across genomics.
Illumina presents the commercial launch of the P3 high-output flow cell for its NextSeq 2000 Sequencing System, significantly enhancing throughput with 1.1 billion reads per run. This innovation expands application versatility and provides customers with cost-effective solutions for deeper genomic insights. The NextSeq 1000 and 2000 systems incorporate advanced informatics and cloud-based genomic compression technology, further optimizing the sequencing process. This rollout indicates a strategic move to strengthen market position by offering affordable pricing and operational efficiency.
Illumina, Inc. (NASDAQ:ILMN) is set to announce its third-quarter 2020 results post-market on October 29, 2020. Following the results, a conference call will be held at 2:00 PM PT (5:00 PM ET) featuring CEO Francis deSouza and CFO Sam Samad, who will discuss financial and operational outcomes. Interested participants can join via Illumina's website or by dialing in. A replay of the call will be available for 30 days afterward.
Illumina Ventures has announced the promotion of Wouter Meuleman to Partner. Meuleman, previously a Principal, was integral to early investments in companies such as Biota Technology, Inc. and Delfi Genomics, Inc. His background includes nine years at Illumina, where he focused on venture investing and technology acquisitions. Illumina Ventures aims to support innovative genomics companies and is committed to advancing biotechnology, especially in light of heightened public health awareness.
FAQ
What is the current stock price of Illumina (ILMN)?
What is the market cap of Illumina (ILMN)?
